Strata Critical Medical, Inc. Class A SRTA

Joby Aviation sits within striking distance of its 52-week low while commercial passenger flights loom on the horizon, and that contradiction raises a question worth examining before the next certification milestone lands.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026, at 2:15 pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company’s website at https://ir.stratacritical.

The National Association of Corporate Directors® (NACD®), the authority on boardroom practices representing more than 24,000 board members, today announced the finalists for the 2026 NACD Directorship 100™ B. Kenneth West Lifetime Achievement Award and Directors of the Year Awards.

Immersion Investment Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Immersion Investment Partners returned 39.1% in the second quarter, surpassing the Russell 2000 Index’s 21.5% gain. The market started valuing their non-AI investments more rationally in the quarter, focusing on strong management, revenue […]

Moby summary of Strata Critical Medical, Inc.'s Q2 2026 earnings call

Strata Critical Medical Inc (SRTA) boosts 2026 outlook after record Q2 performance driven by transplant services and strategic acquisitions.

Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenueQ2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenueAdjusted EBITDA(1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9%Cash flow from operating activities was $5.7 million in

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the second quarter ended June 30, 2026 on Tuesday, August 4, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata’s Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata’s Co-Chief Executive Officer and

Network of experienced transplant surgeons in key markets will immediately become available to all Strata customersAdds significant scale to Transplant Clinical, Strata’s fastest growing business line, with a similar, rapid growth trajectory$21.5 million acquisition completed at mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata’s capital deployment strategy NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Co

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. (“LPS”), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. “The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and So

Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...